| Code | CSB-RA017647MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Alirocumab, targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a secreted serine protease that plays a critical role in cholesterol metabolism by binding to low-density lipoprotein receptors (LDLRs) on hepatocyte surfaces, promoting their degradation in lysosomes. By reducing LDLR availability, PCSK9 decreases the liver's capacity to clear LDL cholesterol from circulation, making it a key regulator of plasma cholesterol levels. Elevated PCSK9 activity is associated with hypercholesterolemia, atherosclerosis, and increased cardiovascular disease risk.
Alirocumab is a fully humanized IgG1 monoclonal antibody approved for treating hyperlipidemia and preventing cardiovascular events in high-risk patients. This biosimilar antibody provides researchers with a valuable tool for investigating PCSK9 biology, lipid metabolism pathways, and cardiovascular disease mechanisms. It supports studies examining PCSK9 inhibition strategies, receptor trafficking dynamics, and cholesterol homeostasis in various experimental models.
There are currently no reviews for this product.